加州大学欧文分校招聘细胞和分子免疫学博士后

时间: 2012-08-21 11:50来源: 未知作者: admin

Postdoctoral Scholar
Dr. Lbachir BenMohamed is seeking applicants for a Postdoctoral Scholar in the Laboratory of Cellular and Molecular Immunology at the Department of Ophthalmology.

The project will focus on herpes immunology, T cell epitope mapping, the assessment and development of a variety of immunological assays systems aimed at optimizing the induction of CD4 and CD8 T cell responses in animal models (HLA transgenic mice, HLA transgenic guinea pigs and HLA transgenic Rabbits) and in humans. These include-epitopes based vaccine using lipopeptides and prime-boost strategies using lipopeptide/Adenoviruses.
There will be ample learning opportunities including how to write manuscript and grants, interaction with other immunology and vaccinology groups at the Institute for Immunology.
Requirements – The candidate must possess a Ph.D., or M.D. / Ph.D. with and expertise in the field of Immunology. Experience in Cellular and molecular Immunology (FACS, cell sorting, Luminex, confocal microscopy, T cell assays etc…) Virology (virus infection in vitro and in vivo, virus titration etc..) and familiarity with animal models (mice, guinea pigs and rabbits) would be advantageous.

Application Procedure – To apply, please send your CV and contact information for three references to:

Lbachir BenMohamed, Ph.D.
Associate Professor/ Director
Laboratory of Cellular and Molecular Immunology
Email: Lbenmoha@uci.edu

The University of California, Irvine is an equal opportunity employer committed to excellence through diversity.

留学人才网http:/liuxuehr.com 为广大海外高层次人才提供回国就业、创业机会,关注海归生活。高层次人才交流QQ群。

  • 千人总群:106247053
  • 北京海归人才群:63984971
  • 上海海归人才群:103237942
  • 重庆海归人才群:172719654
  • 广州海归人才群:169721962
  • 深圳海归人才群:185932597
  • 江苏海归人才群:172331746
  • 浙江海归人才群:314125833
  • 辽宁海归人才群:195244132
  • 吉林海归人才群:314126934
  • 湖北海归人才群:109623634
  • 其它陆续开通...

声明:凡本网注明"来源:XXX"的文/图等稿件,本网转载出于传递更多信息及方便产业探讨之目的,并不意味着本站赞同其观点或证实其内容的真实性,文章内容仅供参考。

  • 留学人才信息发布
  • 企业招聘信息发布
中国留学人才网微信公共平台

更多招聘信息及新闻资讯请扫描二维码关注我们。